# Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

> **NCT01870778** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 6600 (actual)

## Conditions studied

- Acute Heart Failure

## Interventions

- **DRUG:** RLX030
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01870778
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-02
- **Primary completion:** 2017-01-23
- **Final completion:** 2017-02-01
- **Target enrollment:** 6600 (ACTUAL)
- **Last updated:** 2018-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01870778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01870778, "Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01870778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*